Kailera Therapeutics

Obesity biotech Kailera Therapeutics sets terms for $500 million IPO April 17, 2026 News Obesity biotech Kailera Therapeutics prices upsized IPO at $16 high end Kailera Therapeutics, a phase 3 biotech developing injectable and oral GLP-1 agonists for obesity, raised... Read more